OPKO Health
OPK | NASDAQ
$1.62
-$0.06 (-3.57%)
At close: Nov 16, 2026, 4:00 PM ET
$1.62
$0.00 (+0.05%)
After-hours:
Nov 16, 2026, 7:52 PM ET
OPKO Health Company Profile
Company profile explainedCompany Profile
OPKO Health, Inc. operates as a healthcare enterprise with a dual focus on diagnostics and pharmaceuticals. Its operations span the United States, Ireland, Chile, Spain, Israel, Mexico, and other international markets. The company's Diagnostics division encompasses BioReference Laboratories, which delivers a comprehensive suite of laboratory testing services. These services are crucial for disease detection, diagnosis, evaluation, monitoring, and treatment, covering areas such as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare. BioReference serves a diverse client base, including medical practices, clinics, hospitals, employers, and government entities. Additionally, this segment provides a cutting-edge diagnostic instrument system designed for immediate, point-of-care blood test results, alongside its specialized 4Kscore testing for prostate cancer. Within the Pharmaceutical segment, OPKO offers a range of therapeutic products and a robust development pipeline. Key offerings include Rayaldee, indicated for the management of secondary hyperparathyroidism in adults suffering from stage 3 or 4 chronic kidney disease and vitamin D insufficiency. The pipeline features OPK88004, an investigational orally administered selective androgen receptor modulator; OPK88003, a peptide administered once weekly currently in Phase IIb trials for the treatment of type 2 diabetes and obesity; and hGH-CTP, a once-weekly human growth hormone injection that has successfully completed Phase III clinical trials in collaboration with Pfizer, Inc. A core strategy for this segment involves the development and commercialization of proprietary, extended-release versions of existing therapeutic proteins. Furthermore, OPKO Health supplies specialty active pharmaceutical ingredients (APIs) and is involved in the development, manufacturing, marketing, and sale of pharmaceutical, nutraceutical, veterinary, and ophthalmic products. The company also commercializes food supplements and over-the-counter products, produces and sells items primarily within the generics market, and handles the import, marketing, distribution, and sales of pharmaceutical products across various therapeutic areas, including cardiovascular conditions, vaccines, antibiotics, gastro-intestinal ailments, and hormone-related treatments, among others. Its pharmaceutical operations are further bolstered by platforms situated in Ireland, Chile, Spain, and Mexico. Founded in 1991, OPKO Health, Inc. maintains its corporate headquarters in Miami, Florida.
Key Executives
| Name | Position |
|---|---|
| Phillip Frost | Chairman of the Board & CEO |
| Adam E. Logal | Senior Vice President, Chief Financial Officer, Chief Accounting Officer & Treasurer |
| Gary J. Nabel | Chief Information Officer & Director |
| Akhtar Ashfaq | Senior Vice President of Clinical Research & Development and Medical Affairs - Opko Renal |
| Elias Adam Zerhouni | President & Vice Chairman of the Board |
| Gene Yau | Head of Business Development |
| Giovanni Abbadessa | Chief Medical Officer of ModeX |
| Jane H. Hsiao | Vice Chairman of the Board & Chief Technical Officer |
| John R. Mascola | Chief Scientific Officer of ModeX |
| Steven D. Rubin | Executive Vice President of Administration & Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 15, 2026 | 8-K | Current Report |
| Oct 02, 2026 | 8-K | Current Report |
| Aug 28, 2026 | 10-Q/A | [Amend] Quarterly Report |
| Aug 28, 2026 | 10-Q/A | [Amend] Quarterly Report |
| Aug 14, 2026 | 8-K | Current Report |
| Aug 07, 2026 | SC 13D | Filing |
| Jul 28, 2026 | 4 | Filing |
| Jul 28, 2026 | 4 | Filing |
| Jul 27, 2026 | 10-Q | Quarterly Report |
| Jul 27, 2026 | 8-K | Current Report |
OPKO Health
| Country | United States |
| IPO Date | Nov 2, 1995 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 2,275 |
| CEO | Phillip Frost |
Contact Details
4400 Biscayne Boulevard Miami,
Florida 33137 United States
Stock Details
| Ticker Symbol | OPK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000944809 |
| CUSIP Number | 68375N103 |
| ISIN Number | US68375N1037 |
| SIC Code | 2834 |
Recent News
- 12 days ago / marketbeat.comWhat OPKO Health (OPK) Said on Its Q3 Earnings Call
- 12 days ago / seekingalpha.comOPKO Health, Inc. (OPK) Q3 2026 Earnings Call Transcript
- 12 days ago / zacks.comOPKO Health (OPK) Reports Q3 Loss, Misses Revenue Estimates
- 12 days ago / globenewswire.comOPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results
- 20 days ago / globenewswire.comOPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026
- 21 days ago / globenewswire.comOPKO Health's OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001 for Acromegaly
- 1 month ago / benzinga.comOPKO Health Sheds Diagnostics Businesses in Major Labcorp Deal
- 2 months ago / zacks.comHere's Why You Should Retain OPK Stock in Your Portfolio for Now
- 2 months ago / zacks.comOPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026?
- 2 months ago / marketbeat.comOPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Months
Add to Watchlist
Select watchlists to add or remove OPK